龙鳖胶囊对膝骨关节炎大鼠IL-1β、IL-6、IL-10水平的影响

Effects of Longbie Capsule on serum IL-1β, IL-6 and IL-10 of rats with knee osteoarthritis

目的:研究龙鳖胶囊对胶原酶诱导的膝骨关节炎(KOA)的治疗作用,并探讨其作用机制。方法:建立KOA大鼠模型,于造模后开始给予低、中、高剂量的龙鳖胶囊灌胃(0.3125,0.6250,0.9375g/kg),连续4周,观察龙鳖胶囊对KOA大鼠的膝关节肿胀度及血清白细胞介素-1β(IL-1β)、白细胞介素-6(IL-6)、白细胞介素-10(IL-10)水平的影响。结果:造模后,造模组的膝关节肿胀度和IL-1β、IL-6水平均高于对照组(P<0.01),而IL-10水平低于对照组(P<0.01)。给药2周后,与造模组及龙鳖低、高剂量组比较,龙鳖中剂量组的膝关节肿胀度消退较快(P<0.01)。给药3周后,龙鳖低、中、高剂量组的膝关节肿胀度消退均快于造模组(P<0.01),其中,龙鳖中剂量组的膝关节肿胀已消退至对照组水平。给药4周后,与对照组比较,龙鳖低、中、高剂量组的膝关节肿胀度均已消退。给药2、4周后,造模组的IL-1β水平均高于同期对照组及龙鳖低、中、高剂量组(P<0.05);龙鳖低、中、高剂量组的IL-1β水平均高于同期对照组(P<0.05);龙鳖中剂量组IL-1β水平均低于同期龙鳖低、高剂量组(P<0.05);造模组IL-6水平均高于同期对照组及龙鳖低、中、高剂量组(P<0.01,P<0.05);龙鳖低剂量组IL-6水平均低于同期龙鳖中、高剂量组(P<0.05);龙鳖低、中、高剂量组IL-10水平均高于同期对照组和造模组(P<0.01),而其中龙鳖中剂量组IL-10水平均高于同期龙鳖低、高剂量组(P<0.01)。给药2周后,龙鳖低、中、高剂量组IL-6水平均高于对照组(P<0.01);给药4周后,龙鳖胶囊低剂量组IL-6水平与对照组比较,无统计学差异。结论:龙鳖胶囊能消除KOA大鼠的膝关节肿胀,其作用机制与降低KOA大鼠血清IL-1β、IL-6水平及升高IL-10水平有关。

Objective： To study the therapeutic effect of Longbie Capsule on knee osteoarthtitis （KOA） and to explore its possible therapeutic mechanism. Methods： KOA rat model was established. Longbie Capsule in the dose of 0.3125, 0.625, 0.9375g/kg were given by gavage to the model rats for four consecutive weeks. Knee joint swelling and serum interleukin-1β （IL-1β ）, intedeukin-6 （IL-6） and interleukin-10 （IL-10） levels in Longbie Capsule group were observed. Results： Knee joint swelling and the serum levels of IL-1β and IL-6 of model group were higher than that of the control group （P〈0.01）, while the 1L-10 level was lower than that of control group （P〈0.01）. After 2 weeks of medication, knee joint swelling levels of middle-dose Longbie Capsule group decreasedobviously compared with model group, low-dose and high-dose Longbie Capsule group （P〈0.01）. After 3 weeks of medication, knee joint swelling levels of low-dose, middle-dose and high-dose Longbie Capsule group were decreased obviously compared with model group （P〈0.01）, and the knee joint swelling level of low-dose Longbie Capsule group was decreased to the level of control group. After 4 weeks of medication, the knee joint swelling levels of low-dose, middle-dose and high-dose Longbie Capsule group were disappeared. After 2 and 4 weeks of medication, the IL-1β levels of model group were obviously higher than that of control group, low-dose, middle-dose and high-dose Longbie Capsule group at the identical time points （P〈0.05）; the IL-1β levels of low-dose, middle-dose and high-dose Longbie Capsule group were obviously higher than that of control group at the identical time points （P〈0.05）; the IL-1β levels of middle-dose Longbie Capsule group were lower than that of low-dose and high-dose Longbie Capsule groups at the identical time points （P〈0.05）; the IL-6 levels of model group were obviously higher than that of control group, low-dose, middle-dose and high-dose Longbie Capsule group at the identical time points （P〈0.01）; the IL-6 levels of low-dose Longbie Capsule group were lower than that of middle-dose and high-dose Longbie Capsule group at the identical time points （P〈0.01）. The IL-10 levels of low-dose, middle-dose and high-sose Longbie Capsule group were higher than that of contrel group and model group at the identical time points （P〈0.01）; the IL-10 levels of middle-dose Longbie Capsule group were higher than that of low-close and high-dose Longbie Capsnle group （P〈0.01）. After 2 weeks of medication, the IL-6 levels of low- dose, middle-dose and high-dose Longbie Capsule group were higher obviously than that in control group （P〈0.01）; after 4 weeks of medication, the IL-6 levels of low-dose Longbie Capsule group were not significantly different from that of control group. Conclusion： Longbie Capsule can relieve the knee joint swelling, and its mechanism is probably related to the decrease of serum IL-1β and IL-6 levels, and the increase of serum IL-10 level.